INNOVATION DRIVES EVERYTHING

Dr. Falk Pharma in Australia – the experts in digestive and metabolic medicine

Learn more
Organ_Keyvisual_Web_2400x900_1.mp4

Innovation drives everything we do

Dr. Falk Pharma – Innovation drives everything

As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. For over 60 years. 
Our focus: To enable relief, well-being, more ease of movement and confidence in everyday situations for millions of people with inflammatory bowel disease as well as digestive and metabolic problems. With the best possible therapies.

About us

Our products

For the treatment of inflammatory bowel disease, cholestatic liver diseases, eosinophilic oesophagitis, and other diseases

Discover products

Knowledge drives everything

Falk Foundation – scientific dialogue to advance therapeutic progress

Learn more

The diseases we treat

Find in-depth information about chronic diseases of the intestines, oesophagus, and bile ducts.

Learn more
Newsroom Australia, Corporate, Press release, Display on home page, Press release

FDA clearance of IND application for naronapride

27.03.2024

...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US

More

Corporate, Press release

First patient treated in phase iib study of Naronapride in patients with gastroparesis

15.02.2023

Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both…

More

Prometheus Logo
Corporate, Press release

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment

03.01.2022

SAN DIEGO, January 3, 2022 – Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology
company pioneering a precision medicine…

More